BiotechTube
Aphios

Aphios

Woburn, United States· Est.
aphios.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $500K

Overview

Aphios is a privately held, pre-revenue biotech founded in 1999 with a portfolio anchored by 87 patents and $50M in funding. Its strategy combines developing proprietary nanotherapeutics for large markets (e.g., cannabinoids for pain, ginger extract for nausea) with licensing its enabling technology platforms for drug delivery, manufacturing, and pathogen safety. The company structures development through focused LLCs/SPVs, targeting multi-billion dollar opportunities in chronic disease management and biologics safety.

OncologyInfectious DiseaseCNS DisordersSupportive Care

Technology Platform

Integrated enabling technology platforms including SuperFluids® for drug extraction/manufacturing, nanotechnology drug delivery systems (PNS, PNP, CFN), and CFI™ for pathogen inactivation in biologics.

Funding History

2
Total raised:$500K
Grant$300K
Grant$200K

Opportunities

Aphios targets massive, growing markets with its enhanced natural therapeutics, such as the $93B cannabinoid market for chronic conditions.
Its hybrid model offers dual value streams: potential drug royalties and platform licensing fees, particularly for its pathogen reduction technology in the $2.5B biologics safety market.

Risk Factors

The company faces high clinical development risk with a predominantly pre-clinical pipeline and uncertain regulatory paths for natural product nanotherapies.
Financial risk is significant, as advancing multiple programs requires substantial capital beyond the $50M raised to date, and competition in all target markets is intense.

Competitive Landscape

Aphios competes in crowded therapeutic areas (e.g., CINV, pain, anxiety) against large pharma and generic drugs, and in the cannabinoid space against companies like Jazz Pharmaceuticals (Epidiolex). Its differentiation relies on patented nanotechnology for sustained release, but it must prove clinical superiority. In platform tech, it competes with established pathogen reduction and drug delivery firms.

More companies in Small Molecule Drugs →More companies in United States →